The Vanguard Group 13D and 13G filings for Ultragenyx Pharmaceutical Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:16 pm Purchase |
2023-12-29 | 13G | Ultragenyx Pharmaceutical Inc. RARE |
The Vanguard Group | 8,673,432 10.560% |
1,436,909 (+19.86%) |
Filing |
| 2023-09-11 1:33 pm Purchase |
2023-08-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE |
The Vanguard Group | 7,236,523 10.120% |
862,293 (+13.53%) |
Filing |
| 2023-02-09 11:35 am Purchase |
2022-12-30 | 13G | Ultragenyx Pharmaceutical Inc. RARE |
The Vanguard Group | 6,374,230 9.090% |
453,662 (+7.66%) |
Filing |
| 2022-02-10 08:42 am Purchase |
2021-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE |
The Vanguard Group | 5,920,568 8.690% |
270,183 (+4.78%) |
Filing |
| 2021-02-10 11:57 am Purchase |
2020-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE |
The Vanguard Group | 5,650,385 8.570% |
797,226 (+16.43%) |
Filing |